The Biomedical Division of PHC Corporation has received a 2025 R&D 100 Award for its LiCellMo® live cell metabolic pathway analyzer, a tool revolutionizing how laboratories monitor and maintain cell cultures. LiCellMo was recognized for delivering real-time, continuous analysis of key metabolic markers, offering a major advancement in research reproducibility and therapeutic development.
Initially launched in Japan in September 2024 and subsequently rolled out globally, LiCellMo is now available for research applications in the U.S., UK, EU, China, and select Asian markets. Designed to integrate seamlessly with CO2 incubators, it provides labs with minute-by-minute metabolic data without interrupting cell culture conditions.
Key Benefits for Contract Research and Outsourcing Laboratories
- Real-Time Analysis: Enables dynamic tracking of glucose and lactate in live cell cultures.
- Non-Invasive Integration: Preserves culture environments while ensuring accurate monitoring.
- Boosts Reproducibility: Critical for contract labs delivering consistent, high-quality data.
- Versatile Applications: Supports work in CGT, cancer research, and stem cell studies.
By eliminating the need for periodic sampling, LiCellMo minimizes contamination risks and ensures that key metabolic transitions are not overlooked. It leverages proprietary technology initially developed by PHC’s IVD Division for clinical blood glucose monitoring.
Chikara Takauo, Director of PHC Corporation and Head of the Biomedical Division, said, “We are deeply honored that LiCellMo has been recognized with an R&D 100 Award. This innovation empowers researchers with new insights into cell metabolism, particularly in cancer immunology and stem cell research, and supports the advancement of manufacturing processes for next generation therapies.”